Semax

Mechanism of Action

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, comprising the core ACTH(4-7) tetrapeptide extended by a C-terminal Pro-Gly-Pro tripeptide. It was developed at the Institute of Molecular Genetics (IBMCH) of the Russian Academy of Sciences by Nikolai Myasoedov and colleagues beginning in the 1980s. The parent fragment ACTH(4-10) — sequence His-Phe-Arg-Trp-Gly-Lys-Pro — had been characterised earlier for its neurotrophic rather than adrenocortical properties. Semax retains the core neurotrophic tetrapeptide (Met-Glu-His-Phe) and appends the stabilising Pro-Gly-Pro C-terminal extension, which confers resistance to proteolytic degradation in nasal mucosa and brain tissue.

Critically, Semax does not bind the melanocortin receptors (MC1R–MC5R) with meaningful affinity in the manner that full-length ACTH does, and it produces no corticosteroid-stimulating activity at adrenal tissue. This separation of neurotrophic from endocrine activity was the primary design objective. The precise receptor through which Semax exerts its central effects is not fully established — there is no single molecular target identified as definitively as, for example, GLP-1R for semaglutide. The compound's central effects appear to arise from downstream modulation of neurotrophic factor expression and neurotransmitter systems rather than from direct agonism at a single receptor.

The most consistently documented molecular effect of Semax is upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB (tropomyosin receptor kinase B, encoded by NTRK2). BDNF/TrkB signalling activates the MAPK/ERK pathway (via Ras-Raf-MEK-ERK), the PI3K/Akt/mTOR pathway, and PLCγ-IP3-calcium signalling. These cascades promote neuronal survival, synaptic plasticity (including long-term potentiation), dendritic arborisation, and adult hippocampal neurogenesis. Rat studies (Dolotov et al., 2006; Pavlov et al.) demonstrated that intranasal Semax at doses of 50–150 mcg/kg produced statistically significant BDNF mRNA upregulation in the hippocampus and frontal cortex, with effects evident within 1–24 hours. Nerve growth factor (NGF) upregulation in similar tissue preparations has also been reported, suggesting a broader neurotrophic effect.

Semax modulates central neurotransmitter tone. Dopaminergic effects include reported increases in dopamine turnover in prefrontal cortical and striatal regions, which may contribute to improvements in attention and working memory. Serotonergic effects — including modulation of 5-HT2A receptor expression — have been described in rodent brain tissue; these may underlie anxiolytic-like phenotypes observed in elevated plus-maze paradigms. Histaminergic modulation has also been reported. These effects on multiple neurotransmitter systems are consistent with an indirect modulatory profile rather than direct receptor agonism.

In ischaemia models, Semax has demonstrated neuroprotective activity through multiple pathways: suppression of pro-apoptotic gene expression (including BAX and cytochrome c release), attenuation of NF-κB-driven neuroinflammatory gene programmes (TNF, IL-1B, COX-2), reduction of reactive oxygen species in vulnerable perilesional neurons, and upregulation of anti-apoptotic BCL-2 family members. Whether this neuroprotection involves direct action on stressed neurons or is mediated indirectly through glial and vascular cell responses remains incompletely resolved in the literature.

Pharmacokinetics

Semax is administered intranasally and is absorbed through the nasal mucosa, with a portion transported directly to the CNS via olfactory nerve pathways — a route that bypasses the blood-brain barrier and delivers peptide directly to olfactory bulb tissue and adjacent cortical structures. This olfactory-to-CNS pathway is increasingly recognised for small peptides and represents a pharmacokinetically distinct route compared to systemic absorption. A second fraction enters the systemic circulation through the nasal mucous membrane and may reach the brain via the blood-brain barrier, though semaglutide's relative molecular size and peptide nature limit CNS penetration through this route.

Plasma half-life of intranasal Semax in rodents is short — estimated at 10–35 minutes based on plasma disappearance data — but measurable CNS effects in BDNF assays persist for 4–24 hours following a single dose, suggesting that direct olfactory delivery or receptor-mediated effects outlast the pharmacokinetic signal. No formal human pharmacokinetic studies with validated plasma assays have been published in the peer-reviewed Western literature, representing a significant gap in characterisation.

Semax is not orally bioavailable at pharmacologically relevant concentrations due to gastrointestinal proteolysis. Intravenous formulations exist in clinical research contexts and may have a distinct pharmacokinetic profile, with wider tissue distribution but no olfactory-direct CNS delivery.

The Pro-Gly-Pro C-terminal extension contributes meaningfully to proteolytic stability compared to the parent ACTH(4-7) sequence, as demonstrated in in vitro nasal homogenate degradation assays. The primary degradation products are not characterised for independent biological activity.

Reported Effects

Primary Research Findings

• Cognitive performance in cerebrovascular disease: A controlled clinical trial in patients with chronic cerebrovascular insufficiency (n=60 approximately, Russia) demonstrated improvements in attention, short-term memory, and psychomotor speed after 5–10 days of intranasal Semax at 100–300 mcg/day versus placebo. These are the most replicated positive findings in the available literature.
• Acute ischaemic stroke: Semax is registered as a pharmaceutical in Russia for use in acute ischaemic stroke. Clinical trial data from Russian centres (Skvortsova et al.) reported faster neurological recovery and improved functional outcomes (Barthel Index, Rankin scale) in patients receiving intranasal Semax 200–600 mcg/day for 5 days compared to standard care alone. These studies are methodologically limited by small sample sizes and absence of blinding validation, but represent genuine clinical evidence.
• BDNF upregulation in vivo: Rodent studies consistently show hippocampal BDNF mRNA increases 150–250% above baseline following intranasal Semax at 50–150 mcg/kg. NGF upregulation is also reported in similar dose ranges.
• Optic nerve atrophy: Russian clinical studies reported improvement in visual acuity metrics in patients with partial optic nerve atrophy treated with intranasal Semax, providing a basis for its registered ophthalmological indication in Russia.
• Neuroprotection in ischaemia models: In rat middle cerebral artery occlusion models, Semax at 25–100 mcg/kg administered intranasally or IV reduced infarct volume by 20–40%, with better outcomes on neurological deficit scoring, particularly when administered within 1–4 hours of onset.

Secondary / Emerging Findings

• Attention deficit and ADHD-like phenotypes: Preliminary Russian clinical data and anecdotal reports suggest attentional benefits in individuals with ADHD-like presentations. The dopaminergic modulatory effects provide a plausible mechanistic basis. No Western RCT data is available.
• Anxiolytic-like effects: Rodent studies using elevated plus-maze and forced swim paradigms report anxiolytic and antidepressant-like effects. These are consistent with 5-HT and dopamine modulation but have not been confirmed in controlled human trials.
• Stress resilience: Healthy volunteer studies at the Institute of Molecular Genetics reported reduced cognitive decrements under experimentally induced psychogenic stress in Semax-treated subjects. Sample sizes were small.
• Anti-inflammatory CNS effects: Semax has been reported to reduce expression of pro-inflammatory gene clusters in brain tissue post-injury in rodent models, including C3, C1q, and complement-related transcripts.

Effects Not Yet Demonstrated in Humans

The BDNF/TrkB signalling upregulation documented in rodent hippocampal and cortical tissue is the putative basis for most claimed cognitive and neuroprotective effects. However, no study has confirmed BDNF protein elevation in human CSF or brain tissue following Semax administration. Human PET neuroimaging, CSF biomarker, or biopsy data validating target engagement in people do not exist in the accessible literature.

The anxiolytic and antidepressant-like effects compelling in rodent paradigms have not been tested in controlled human trials with validated psychiatric rating scales. Reported anecdotal benefits should not be taken as surrogate evidence for clinical efficacy.

Dosing & Administration

The clinically studied and registered dose range for intranasal Semax in Russia is 200–600 mcg per day, administered as nasal drops or spray. Russian pharmaceutical preparations are typically available as 0.1% (1 mg/mL) or 1% (10 mg/mL) solutions. A single drop from standard nasal preparations delivers approximately 50 mcg. Most clinical protocols use 2–3 drops per nostril twice daily, yielding 400–600 mcg total daily dose.

Research community practice outside of Russia typically uses similar dose ranges: 200–400 mcg/day for general cognitive purposes, with higher doses of 500–600 mcg/day sometimes employed for acute neuroprotective applications. Cycle lengths in research contexts range from 7 to 14 days, with intervals between cycles. Continuous use has not been formally studied for safety.

The intranasal route is preferred for reasons of direct CNS delivery and practical convenience. Subcutaneous injection is an alternative route used in some research contexts, with the advantage of more reliable systemic absorption but loss of the direct olfactory-CNS delivery pathway. No oral formulation has demonstrated adequate bioavailability.

Timing considerations: morning or midday administration is common in research practice given the stimulatory profile. Evening dosing has been reported to disrupt sleep in some individuals, though this has not been systematically evaluated. There is no established meal-timing requirement.

The literature does not provide guidance on optimal duration of use, tolerance development, or need for cycling. The Russian pharmaceutical registrations cover short-term use (5–14 days) for acute conditions; longer-term use profiles are not formally characterised.

Side Effects & Safety Profile

Commonly Observed

Mild nasal irritation, including transient burning or discomfort at the nasal mucosa, is the most commonly reported adverse effect of intranasal administration and is typically brief and self-limiting. Headache occurs in a subset of users and is reported in clinical trial data, though incidence rates are not consistently documented across studies. Mild transient stimulation — described as heightened alertness or mild tension — is commonly noted at higher doses.

Less Common

Mild elevation in anxiety at higher doses has been reported in some subjects. This appears paradoxical given the anxiolytic profile in rodent models, and may reflect individual neurotransmitter baseline variability. Vivid dreaming or sleep disruption has been noted with evening dosing. These effects are not well characterised in controlled data.

Contraindications & Warnings

No serious adverse events attributable to Semax have been reported in the published clinical trial literature, including Russian-language sources. The absence of known serious adverse events should be interpreted with appropriate caution given the limited sample sizes, short study durations, and narrow patient populations studied. Long-term safety data beyond 14-day treatment courses do not exist in the controlled literature.

A meaningful methodological concern is that Russian clinical trials forming the evidence base have not been independently replicated by Western institutions using modern trial standards (GCP, pre-registration, independent statistical analysis). The possibility of publication bias and outcome reporting bias cannot be excluded. Researchers sourcing Semax outside of pharmaceutical manufacturers should be aware that purity, stability, and dosing accuracy in research-grade peptide products vary considerably.

Use in pregnancy or lactation is not characterised. Use in paediatric populations is not formally established. Interactions with MAO inhibitors or other serotoninergic compounds have not been studied.

Clinical Evidence

The clinical evidence base for Semax is regional and methodologically heterogeneous. The compound is registered as a pharmaceutical in Russia and Ukraine for the following indications: acute ischaemic stroke (acute phase), transient ischaemic attack, chronic cerebrovascular insufficiency, traumatic brain injury, and optic nerve atrophy. This registration is based on clinical trial data conducted at Russian centres, primarily the Neurological Institute of the Russian Academy of Medical Sciences and institutes affiliated with IBMCH.

The Skvortsova et al. trials in acute ischaemic stroke are the most cited in English-language secondary literature. These reported improved neurological outcomes on the Scandinavian Stroke Scale and Barthel Index in patients receiving Semax as adjunct to standard care. Published in Russian-language journals with English abstracts, they report statistically significant differences but methodological details (randomisation, blinding, allocation concealment) are not fully described in accessible versions.

Cognitive function studies in patients with cerebrovascular insufficiency and mild cognitive impairment represent the second largest body of clinical evidence, again from Russian institutions. These showed improvements in attention tests (trail-making, digit span) but did not use standardised neuropsychological batteries comparable to those used in Western MCI trials.

The ophthalmological data for optic nerve atrophy has been reported by researchers at Russian ophthalmology institutes, with visual evoked potential and acuity improvements noted. These have not been replicated by independent groups.

Western peer-reviewed literature on Semax is largely limited to mechanistic animal studies. PubMed-indexed English-language RCT data in humans does not exist at time of writing.

Evidence grade: C+. The compound has genuine pharmacological mechanisms and regional pharmaceutical registration based on clinical trial data, but the evidence base does not meet modern Western standards for Phase II/III confirmation. The absence of independent replication is a critical limitation.

Interaction Considerations

No formal drug-drug interaction studies for Semax exist in the published literature. Given its dopaminergic and serotonergic modulatory properties, the following interactions are theoretically relevant:

• Monoamine oxidase inhibitors (MAOIs): potential for serotonin syndrome-like effects, given Semax's serotonergic modulation; avoid combination absent specific guidance.
• Stimulant medications (methylphenidate, amphetamines): additive stimulatory and dopaminergic effects are plausible; combined use has not been studied.
• Anxiolytic and sedative medications (benzodiazepines, SSRIs): direction of interaction unclear given Semax's mixed profile; pharmacokinetic interactions are unlikely but pharmacodynamic interactions cannot be excluded.
• Cholinesterase inhibitors (donepezil, rivastigmine): combined use in neuroprotective contexts has been proposed in the Russian literature but is not supported by controlled interaction data.

In research contexts, Semax is sometimes combined with Selank (another Russian synthetic peptide with anxiolytic properties) or with racetam nootropics. The safety and efficacy of these combinations are not characterised.

Discovery & Research Timeline

• 1971–1983 — ACTH fragments studied for behavioural and neurotrophic effects by de Wied and colleagues in the Netherlands. ACTH(4-10) identified as the behaviorally active fragment retaining memory and attentional effects without adrenocortical activity.
• 1980s — Nikolai Myasoedov and colleagues at the Institute of Molecular Genetics (IBMCH), Moscow, initiate systematic development of stabilised ACTH fragments. The Pro-Gly-Pro C-terminal extension is added to create the Semax heptapeptide sequence.
• 1991 — Early pharmacological characterisation of Semax published in Russian-language literature. BDNF-upregulating properties noted in rodent brain tissue.
• Mid-1990s — Clinical studies initiated in Russia for acute ischaemic stroke and cerebrovascular disorders. Development supported by the Russian Academy of Sciences.
• 2000s — Clinical registration in Russia and Ukraine. Semax approved as a pharmaceutical for stroke, TBI, and cerebrovascular insufficiency. Ophthalmological indication added based on optic nerve data.
• 2003–2006 — Dolotov, Pavlov, and colleagues publish detailed mechanistic studies on BDNF upregulation and neuroprotection mechanisms in rodent models, providing molecular basis for clinical observations.
• 2011 — Pharmaceutical manufacturing and distribution formalised in Russia under registration. Nasal drop formulation standardised.
• 2010s — Growing international interest in Semax driven by nootropic communities. Research-grade peptide suppliers begin distributing internationally. Mechanistic studies continue in Eastern European academic institutions.
• 2020s — Increasing PubMed-indexed publications from Eastern European groups; modest uptake by Western researchers. No Western Phase I/II trials registered or completed. Some overlap with broader academic interest in BDNF-targeted interventions for neurodegeneration.

Research Disclaimer

The information presented in this article is compiled from peer-reviewed literature, grey literature, and registered pharmaceutical data for educational and research purposes. Semax is a pharmaceutical registered in Russia and Ukraine and is not approved by the FDA, EMA, or other major Western regulatory agencies. In most Western jurisdictions, Semax is an unapproved research compound. The clinical trial evidence base, while genuine, does not meet modern Phase II/III standards as applied by Western regulatory agencies. The neuroprotective, cognitive, and anxiolytic effects described have not been independently confirmed in Western-conducted controlled trials. This article does not constitute medical advice, a diagnosis, or a treatment recommendation. Researchers should independently verify safety profiles and be aware that purity and sterility of commercially available research-grade Semax products are not regulated to pharmaceutical standards outside of Russia and Ukraine.

Community Research Notes

"The focus on Semax is different from stimulants. Caffeine gives me energy and a bit of jitteriness. Semax gives me what I'd describe as precision — like the signal-to-noise ratio in my thinking went up. Distractions still exist, I'm just less pulled toward them. It kicks in within 20 to 30 minutes of intranasal dosing and lasts maybe four to six hours. I cycle it two weeks on, two weeks off."

— Community researcher, cognitive enhancement protocol

"I run Semax and Selank together most mornings — two drops Semax in one nostril, two drops Selank in the other. Semax alone occasionally gives me a mild edge of tension if I'm already stressed. Selank takes that off completely. Together they produce what I can only call clean, calm alertness. It's become my most consistent nootropic stack. I've used it six months total across several cycles."

— Self-experimenter, Semax + Selank combination stack

"The mood component surprised me. I expected cognitive effects and got them, but the uplift in motivation and general sense of engagement with work was stronger than I anticipated. I was in a fairly flat period before starting — not depressed, just unmotivated — and within four days there was a noticeable shift. Whether it's BDNF, dopamine, or something else, I can't say. But it was real."

— Community researcher, mood and motivation effects

"People in nootropic communities talk about 'laser focus' with Semax and that's exactly right. During a 10-day run on 400mcg per day, I had three or four sessions of genuinely exceptional focused work — the kind where hours disappear. It didn't happen every day and I couldn't force it, but when it hit, it was the best cognitive state I've had from any compound I've tried. NA-Semax Amidate felt roughly 40% stronger per microgram by my estimate."

— Experienced peptide researcher, comparative dosing notes

Frequently Asked Questions

What is the difference between Semax and NA-Semax Amidate?

N-Acetyl Semax Amidate (NASSA) is a chemically modified version of Semax with two structural changes: N-acetylation at the methionine N-terminus and C-terminal amidation. Both modifications substantially increase resistance to proteolytic degradation in nasal mucosa, which is the primary site of peptide breakdown following intranasal administration. The practical consequence is that NA-Semax Amidate is estimated to be roughly two to three times more potent per microgram than standard Semax when administered intranasally. Effective doses for NASSA therefore start lower — commonly cited in the 50–200mcg range — while standard Semax is typically used at 200–600mcg. Both share the same mechanistic profile; NASSA simply delivers more active compound to the CNS per dose.

Is Semax stimulating or calming?

Semax is primarily activating and focusing in its subjective profile, particularly at doses of 300mcg and above. It is not a stimulant in the classical sense — it does not produce the cardiovascular activation, appetite suppression, or crash associated with amphetamines or high-dose caffeine. The effect is better described as enhancement of signal clarity and attentional focus. At lower doses some users report mild anxiolytic effects consistent with the rodent pharmacology. At higher doses or in individuals with anxiety-prone baselines, mild increase in tension is occasionally reported. The dopaminergic and serotonergic modulation means the subjective profile is context- and individual-dependent. Evening dosing is typically avoided due to reported sleep disruption.

How quickly do nootropic effects appear?

Community reports consistently describe onset of cognitive effects within 20 to 40 minutes of intranasal administration, with peak effects in the one to three hour window and a total duration of four to eight hours depending on individual response and dose. This acute profile is consistent with the pharmacokinetic data showing rapid CNS delivery via the olfactory route. Longer-term effects related to BDNF upregulation and synaptic remodelling, if they occur in humans as documented in rodents, would be expected to accumulate over days to weeks of use and may outlast the acute pharmacokinetic signal — though this has not been confirmed with human biomarker data.

Can Semax be used daily or should it be cycled?

Russian pharmaceutical protocols for acute conditions (stroke, TBI) typically cover five to fourteen day courses. Research community practice for cognitive enhancement generally uses cycles of four to eight weeks with rest intervals of equal or greater length. The rationale for cycling includes the possibility of receptor downregulation at the BDNF/TrkB level and the general precautionary principle for compounds modulating neurotrophic factor expression. Whether Semax actually produces meaningful tolerance or desensitisation with continued use is not established by clinical data. Some researchers use it at lower doses more continuously; others prefer concentrated short cycles. Daily use beyond fourteen days is not characterised in any controlled study.

What makes the Semax + Selank combination popular?

The combination is popular because the two peptides have complementary but non-overlapping profiles. Semax is activating and focusing, with some users experiencing mild anxiety at higher doses. Selank is anxiolytic and calming without being sedating. Administered together — typically 300–400mcg each intranasally — they produce a state described as calm, focused alertness: Semax sharpens cognition while Selank removes the edginess that can accompany it. Both were developed at the same Russian institution (IBMCH), both act on overlapping neurotrophic and neurotransmitter systems, and both have a plausible mechanistic rationale for the combination. Community experience over more than a decade has reinforced this as one of the most reliable peptide stacks for cognitive work.

Compounds That Pair Well

Selank — The primary and most widely validated pairing. Selank is an anxiolytic nootropic that modulates GABA and serotonin tone without sedation. Where Semax activates and focuses, Selank reduces anxiety and smooths the cognitive edge. Together they produce a balanced state that neither compound achieves alone. The combination is the most commonly reported Semax stack in research communities and is mechanistically coherent. Both compounds were developed at the same institute in Moscow, and the combination is mentioned in Russian research literature.

BPC-157 — Added to Semax stacks for general neuroprotection and systemic health support. BPC-157's documented effects on gut-brain axis integrity, angiogenesis, and tissue repair provide a broad systemic base that may support the central effects of Semax. Some researchers hypothesise that BPC-157's anti-inflammatory properties complement Semax's neuroprotective mechanisms in high-stress or recovery contexts. The combination is not mechanistically redundant, as the two compounds operate through largely distinct pathways.

Epithalon — Used in combined cognitive and longevity protocols. Epithalon's telomerase activation and pineal-regulatory effects address longer-term cellular ageing and circadian health, while Semax provides the acute cognitive modulation. The protocols operate on different timescales — Epithalon as a periodic multi-week course for systemic effects, Semax in shorter focused cycles — and the compounds can run concurrently without obvious interaction. This pairing is more common in protocols aimed at both cognitive performance and healthspan.

Dihexa — An advanced experimental combination for researchers with significant experience. Dihexa is a hepatocyte growth factor (HGF) potentiator with reported synaptogenic effects at extremely low doses. Like Semax, it is proposed to act via neurotrophic mechanisms, but through HGF/Met receptor signalling rather than BDNF/TrkB. The two compounds are sometimes combined in experimental nootropic protocols on the hypothesis that parallel neurotrophic pathway activation may produce additive or synergistic cognitive effects. The combination is poorly characterised and represents a higher-risk approach intended for experienced researchers only.

---

Build Your Personalised Protocol

Semax is one of many compounds available in the BioStack Generator. Explore nootropic stacks alongside other cognitive enhancement compounds.

Get Your BioStack →